PEAK6’s Crinetics Pharmaceuticals CRNX Stock Holding History

PEAK6’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$511K	–	3097
2024 Q4	$511K	Buy	+10,000	New	+$559K	﹤0.01%	2142

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6's CRNX Position: Q1 2025 in Review

PEAK6 sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 10,000 shares — an estimated $511K sold.

PEAK6 first reported a position in CRNX in Q4 2024 and held it in 1 quarter. The position peaked at $511K in Q4 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

PEAK6 reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 10,000 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $511K.
PEAK6 first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 1 quarter.
PEAK6's Crinetics Pharmaceuticals position peaked at $511K in Q4 2024.
227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.